Covington & Burling has represented Tokyo-based Astellas Pharma on its $3 billion acquisition of U.S. drugmaker Audentes Therapeutics, which was advised by Fenwick & West.

According to Reuters, the acquisition marks the second biggest on record for Astellas after its 2010 purchase of OSI Pharmaceuticals Inc for $3.8 billion. Astellas expects the deal, which is subject to regulatory approval, including U.S. antitrust clearance, to close in the first quarter of 2020.

Reuters added that this sale was a push by Astellas Pharma to make genetic medicines a key area of growth. Gene therapies are one of the hottest areas of drug research and Astellas is offering $60 per share in cash for San Francisco-based Audentes.

Morgan Stanley and Centerview Partners are acting as financial advisors to Astellas and Audentes, respectively.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com. 

Related Articles

Features

MIDDLE EAST REPORT: Korea on the Horizon

by Nimitt Dixit |

As the historic economic partnership between the UAE and South Korea takes effect, lawyers in both countries are building capabilities across multiple practice areas to help clients navigate unfamiliar regulatory environments through specialised practice groups and strategic alliances.

Deals

Skadden advises Cemex on $650 mln Philippines divestment

by Nimitt Dixit |

U.S. law firm Skadden, Arps, Slate, Meagher & Flom has advised Mexico-based multinational building materials company Cemex on the sale of its operations and assets in the Philippines to Dacon Corporation, DMCI Holdings, and Seminara Mining and Power Corporation.

Deals

Latham, CAM advise on $370 mln India gas deal

by Nimitt Dixit |

Latham & Watkins and Cyril Amarchand Mangaldas have advised a Japanese consortium on its $370 million primary investment into India’s AG&P LNG Marketing.